sarilumab - Articles and news items

cimzia arthritis x-ray hands bones

Sanofi and Regeneron announce EMA acceptance for review of Marketing Authorisation Application for sarilumab

Industry news / 1 August 2016 / Sanofi / Regeneron Pharmaceuticals, Inc.

Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis…

sarilumab demonstrates superiority to adalimumab in rheumatoid arthritis

Industry news / 11 March 2016 / Victoria White

A Phase III study demonstrated that sarilumab was superior to adalimumab in improving signs and symptoms in patients with active RA…

Asia-Pacific rheumatoid arthritis treatment market value will reach $7 billion by 2021, says GBI Research

Industry news / 2 June 2015 / Victoria White

The rheumatoid arthritis therapeutics market in the APAC region will expand in value from $5.6 billion in 2014 to an estimated $7 billion by 2021…

Sanofi and Regeneron announce positive topline results from Phase 3 studies with sarilumab in patients with rheumatoid arthritis

Industry news / 21 May 2015 / Victoria White

Phase 3 study of sarilumab met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis…


Sanofi and Regeneron announce new, detailed data from positive sarilumab Phase 3 rheumatoid arthritis trial at EULAR

Industry news / 12 June 2014 / Sanofi

Sanofi and Regeneron Pharmaceuticals, Inc. presented positive results from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis patients who were inadequate responders to methotrexate therapy…


Sanofi and Regeneron announce patient enrollment in two Phase 3 trials with sarilumab in RA

Industry news, News / 15 May 2013 / Sanofi

Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials…

Sanofi and Regeneron report positive Phase 2b trial results with sarilumab in rheumatoid arthritis

Industry news, News / 12 July 2011 / Sanofi

Sanofi and Regeneron Pharmaceuticals, Inc. announced results from Phase 2b trials…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...